Elacestrant versus Standard Endocrine Therapy in Women and Men with Node positive, Estrogen Receptor positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence—A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
Pantai Hospital Kuala Lumpur
PRINCIPAL INVESTIGATOR
Dr Mastura Md Yusof
CONTACT
CRC: 03-22960888 Ext.1320, 1321, 1322
A Phase III,Open Label, Randomised study to Assess the Efficacy and Safety of Extend Therapy with Camizestrant (AZD9833, a Next Generation , Oral Selective Estrogen Receptor Degrade) Versus standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in patient with ER+/HER2- Early Breast Cancer and an intermediate or High Risk of Recurrence Who have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine–Based Therapy without Disease Recurrence. (CAMBRIA-1)
Prince Court Medical Centre
PRINCIPAL INVESTIGATOR
Dr Muhammad Azrif Ahmad Annuar
CONTACT
SC: Punitha Somasundram
Email: punitha.somasundram@princecourt.com
A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice in Participants With Triple Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) At Surgery (TroFuse-012)
Prince Court Medical Centre
PRINCIPAL INVESTIGATOR
Dr Muhammad Azrif Ahmad Annuar
CONTACT
SC: Tan Woan Lee
Email: woanlee.tan@princecourt.com
Pantai Hospital Kuala Lumpur
PRINCIPAL INVESTIGATOR
DR MASTURA BINTI MD YUSOF
drmasturamy@gmail.com
03 – 2296 0764
CONTACT
General Line: 03 – 2296 0888
CRC: 03-22960888 Ext.1320, 1321, 1322
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
CHOONG SWEE HSIA
CONTACT
SC: Nurun Nadihah Norazam
Pantai Hospital Kuala Lumpur
PRINCIPAL INVESTIGATOR
DR MASTURA BINTI MD YUSOF
drmasturamy@gmail.com
03 – 2296 0764
CONTACT
General Line: 03 – 2296 0888
CRC: 03-22960888 Ext. 1321, 1322
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
IZZATI BINTI WAN MAHARUDDIN
CONTACT
SC: Nur Syaza Mirza Omar
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
(Facebook)
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
ADLINDA ALIP
CONTACT
SC: Hanisya
Contact no: 03-79492120
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (TROPION-Breast04)
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
CHOONG SWEE HSIA
CONTACT
SC: Nurun Nadihah Norazam
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
Dr Adlinda Alip
CONTACT
SC: Haniesya
General line:03-79492120